Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: Fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan

Leukemia

Volumn 21, Issue 10, 2007, Pages 2109-2116

  Shimoni, A ^a   Hardan, I ^a   Shem Tov, N ^a   Rand, A ^a   Herscovici, C ^a   Yerushalmi, R ^a   Nagler, A ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CONTROL; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESEARCH; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG FATALITY; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; KIDNEY DISEASE; LIVER DISEASE; LIVER DYSFUNCTION; LIVER VENOOCCLUSIVE DISEASE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PREDICTION; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

EID: 34548769294     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404886     Document Type: Article

References (39)

1. Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE et al. Bone marrow transplantation. N Engl J Med 1975; 292: 832-843.
2. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: A review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661-1672.
3. Shimoni A, Nagler A. Nonmyeloablative stem cell transplantation: Lessons from the first decade of clinical experience. Curr Hematol Rep 2004; 3: 242-248.
4. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: Non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29.
5. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity. Leukemia 2006; 20: 322-328.
6. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
7. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
8. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
9. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
10. Shimoni A, Nagler A. Non-myeloablative stem cell transplantation (NST): Chimerism testing as guidance for immune-therapeutic manipulations. Leukemia 2001; 15: 1967-1975.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos 1958; 53: 457-481.
12. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
13. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783.
14. Van Besien K, Smith S, Anastasi J, Larson R, Thirman M, Cidenike T et al. Irreversible myelosuppression after fludarabine-melphalan conditioning: Observations in patients with graft rejection. Blood 2004; 103: 4373-4374.
15. Westerhof GR, Ploemacher RE, Boudewijn A, Blokland I, Dillingh JH, McGown AT et al. Comparison of different busulfan analogues for depletion of hematopoietic stem cells and promotion of donor-type chimerism in murine bone marrow transplant recipients. Cancer Res 2000; 60: 5470-5478.
16. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550-1558.
17. Shimoni A, Kroger N, Zabelina T, Ayuk F, Hardan I, Yeshurun M et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age > 55 years) with hematologic malignancies: Older age is no longer a contraindication when using reduced intensity conditioning. Leukemia 2005; 19: 7-12.
18. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810-1814.
19. Blaise DP, Michel Boiron J, Faucher C, Mohty M, Bay JO, Bardoux VJ et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005; 104: 1931-1938.
20. Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M et al. outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969-2976.
21. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616-1623.
22. Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336-342.
23. Van Besien K, Devine S, Wickrema A, Jessop E, Amin K, Yassine M et al. Regimen-related toxicity after fludarabine-melphalan conditioning: A prospective study of 31 patients with hematologic malignancies. Bone Marrow Transplant 2003; 32: 471-476.
24. Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R et al. Nonmyeloablative transplantation with or without alemtuzumab: Comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121-3127.
25. Dasgupta RK, Rule S, Johnson P, Davies J, Burnett A, Poynton C et al. Fludarabine phosphate-and melphalan: A reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect. Bone Marrow Transplant 2006; 37: 455-461.
26. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-itensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: Dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004; 104: 865-872.
27. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin' disease: Low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005; 35: 943-951.
28. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al. Nonmyeloablative stem cell transplantation is an effective therapy foe refractory or relapsed hodgkin lymphoma: Results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12: 172-183.
29. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple, myeloma. Bone Marrow Transplant 2002; 30: 367-373.
30. Kroger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/ fludarabine-based dose-reduced altogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698-708.
31. Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004; 104: 3865-3871.
32. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5728-5738.
33. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10: 178-185.
34. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
35. Antin JH, Ferrara JL. Cytokine dysrequlation and acute graft-versus-host disease. Blood 1992; 80: 29647-2968.
36. Hill GR, Crawford JM, Cooke KR, Brinson-YS, Plan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: The role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-3213.
37. Johansson JE, Brune M, Ekman T. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning. Bone Marrow Transplant 2001; 28: 737-742.
38. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871.
39. Valcarcel D, Martino R, Sureda A, Canals C, Altes A, Briones J et al. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. Eur J Haematol 2005; 74: 144-151.